Date & Time of Session - 3/10/26 - from 12:00 - 1:00PM

Overview
Sjögren's Syndrome represents a significant and growing clinical challenge in rheumatology and primary care. Sjögren's Syndrome remains underrecognized and often diagnosed years after symptom onset. The increasing prevalence of autoimmune diseases, combined with improved diagnostic criteria and heightened clinical awareness, makes understanding these disease states essential.

Healthcare professionals must stay informed about emerging therapeutic developments in Sjögren's Syndrome, particularly given that no FDA-approved disease-modifying therapies currently exist for this condition. 

Objectives
Upon completion of this activity, participants will be able to:
1. Describe the prevalence, epidemiology, etiology, and pathophysiology of Sjögren’s Syndrome 
2. Identify the clinical manifestations and diagnostic criteria for Sjögren’s Syndrome
3. Apply established diagnostic criteria for Sjögren’s Syndrome
4. Summarize clinical trial–supported guidelines and evidence for the management of Sjögren’s Syndrome
5. Discuss emerging pipeline therapies and ongoing clinical trials supporting their potential use for Sjögren’s Syndrome
6. Assess emerging pipeline therapies and ongoing clinical trials supporting their potential use for Sjögren’s Syndrome

Target Audience
Pharmacists, residents, and students

Special Services
If you require special assistance to attend this event, please call Megan Russell at (304) 550-0896.

Speaker:
Jacob Johnson, PharmD
PGY1 Community Based Resident @UKHC Specialty Pharmacy
UK College of Pharmacy - Lexington, Kentucky